Physician profile
Deepak Khosla
NPI 1679574701
$2,997.65
in general payments reported to CMS, 2019-2025
21 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $162 · 2021: $590 · 2022: $240 · 2023: $591 · 2024: $294 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $750.32 | 2019-2025 | 2nd Gen Centrimag Primary Console, Aveir, Triclip |
| Novartis Pharmaceuticals Corporation | $239.05 | 2019-2022 | |
| Boston Scientific Corporation | $230.66 | 2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $199.36 | 2022-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $190.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $186.36 | 2019-2023 | Camzyos |
| Medtronic, INC. | $157.42 | 2023-2024 | Venaseal, Micra |
| Abiomed | $145.00 | 2021-2024 | Impella |
| Merck Sharp & Dohme LLC | $136.89 | 2022-2023 | Verquvo |
| Amgen INC. | $135.60 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.07 | 2025 | |
| Janssen Pharmaceuticals, INC | $96.04 | 2019-2022 | |
| Bridgebio Pharma, INC. | $84.94 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.77 | 2019-2022 | |
| Bardy Diagnostics, INC. | $65.00 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $39.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.46 | 2019 | |
| Pfizer INC. | $22.83 | 2019 | |
| Akcea Therapeutics, INC. | $21.97 | 2020 | |
| Chiesi USA, INC. | $17.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Khosla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.